Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.

Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.

BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence...

Full description

Bibliographic Details
Main Authors: Stewart, B, Jobarteh, M, Sarge-Njie, R, Alabi, A, de Silva, T, Peterson, K, Peterson, I, Whittle, H, Rowland-Jones, S, Jaye, A, Cotten, M, Mendy, M
Format: Journal article
Language:English
Published: BioMed Central 2011
Subjects:
Viruses
Pharmacology
Infectious diseases
Africa

Similar Items

Similar Items